Search - tctmd.com

Displaying 101 - 120 of 295

Sort: Relevancy | Date

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Todd Neale

August 27, 2016

News Opinion Editor's Corner

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

Shelley Wood

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

CLEAN-TAVI:TAVR 脑栓塞预防结果公布

Yael L. Maxwell

August 15, 2016

News Daily News

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Yael L. Maxwell

August 15, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Daily News

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Michael O'Riordan

June 07, 2016

News Daily News

房颤 TAVR 后相关死亡和出血风险增加

Michael O'Riordan

April 18, 2016

News Daily News

La FA Post-TAVR se Asocia a un Mayor Riesgo de Mortalidad y Hemorragias

Michael O'Riordan

April 18, 2016

News Daily News

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Michael O'Riordan

April 18, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Opinion Editor's Corner

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Shelley Wood

March 28, 2016

Advertisement

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

New ESC A-fib Guidelines Call for Integrated Care for All Patients

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

CLEAN-TAVI:TAVR 脑栓塞预防结果公布

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

What TAVR Needs Next . . . and What It’s Getting

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

房颤 TAVR 后相关死亡和出血风险增加

La FA Post-TAVR se Asocia a un Mayor Riesgo de Mortalidad y Hemorragias

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content